# Metagenomi Therapeutics, Inc. (MGX)

> Source: Nexqual · https://nexqual.com/MGX · data as of 2026-10-15 20:00 UTC · cite as "Nexqual, Metagenomi Therapeutics, Inc. (MGX), nexqual.com/MGX" · informational, not investment advice.

**Price:** USD 0.85 (-1.86% on the day) · last close of Oct 15, 2026; US market closed, not a live price. Prev close 0.86 · day 0.84–0.88 · 52w 0.84–3.4 · market cap $31.9M · NMS

## Key facts
- Analysts: Buy (mean 2.20 on a 1–5 scale) (5 analysts), mean target USD 7 (range 5–9).
- Total return with dividends: 1Y -74.6% vs S&P 500 +18.1%; 5Y -91.8% vs S&P 500 +85.1%.

## Analysts
Consensus Buy (mean 2.20 on a 1–5 scale), 5 analysts; mean target USD 7 (low 5, high 9).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-11 | Wells Fargo | Target lowered | Overweight | $9 → $7 |
| 2026-07-07 | Chardan Capital | Target lowered | Buy | $7 → $5 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-16) | 5Y (from 2024-02-05) |
|---|---|---|
| Total return | -74.6% | -91.8% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -74.7% | -60.5% |
| Volatility (annualized) | 57.6% | 80.6% |
| Max drawdown | -74.8% (Oct 2025→Oct 2026) | -93.1% (Feb 2024→Oct 2026) |

## Peers (Biotechnology)
RYTM (Rhythm Pharmaceuticals, Inc.) USD 87.97 +1.57% · BLTE (Belite Bio, Inc) USD 152.62 +0.49% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.72 +1.52% · PRAX (Praxis Precision Medicines, Inc) USD 248.24 +2.01% · IONS (Ionis Pharmaceuticals, Inc.) USD 44.12 +4.11% · SYRE (Spyre Therapeutics, Inc.) USD 80.1 -0.44%

## More
Full page: https://nexqual.com/MGX · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt